4.3 Article

Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China

期刊

CLIMACTERIC
卷 25, 期 3, 页码 286-292

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/13697137.2021.1956894

关键词

Estradiol; dydrogesterone; menopausal hormone therapy; vasomotor symptoms

资金

  1. Abbott

向作者/读者索取更多资源

The study showed that continuous combined ultra-low-dose estradiol and dydrogesterone can effectively reduce vasomotor symptoms and improve the quality of life in postmenopausal women in China.
Objective This study aimed to evaluate the efficacy and safety of ultra-low-dose estradiol plus dydrogesterone for vasomotor symptoms in postmenopausal women in China (trial registration CTR20160689). Methods A total of 332 patients were randomized to continuous combined estradiol 0.5 mg + dydrogesterone 2.5 mg or placebo for 12 weeks. The primary efficacy endpoint was change in the number of hot flushes per day from baseline to end of treatment. Secondary efficacy endpoints included change in the number of moderate-to-severe hot flushes per day, menopausal symptoms from baseline and quality of life. Results Between baseline and end of treatment, change in the mean number of hot flushes per day was -5.9 (95% confidence interval [CI] - 6.6, -5.2) with estradiol + dydrogesterone and -4.5 (95% CI -5.1, -3.8) with placebo, with a mean difference of -1.4 hot flushes per day (95% CI -2.2, -0.7; p < 0.001). Significant differences in favor of estradiol + dydrogesterone were also observed in several secondary efficacy endpoints. The study treatment was well tolerated. Conclusion Continuous combined estradiol 0.5 mg + dydrogesterone 2.5 mg reduced hot flushes in postmenopausal women in China. This ultra-low-dose regimen provides an additional option for women experiencing the vasomotor symptoms of menopause. These data are consistent with previous results in other populations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据